The RITUXAN for RA EXPERIENCE Program

 

through Genentech
Rheumatology
Access Solutions

$4,000 per
12-month period
toward the cost of
Rituxan for eligible patients

Learn More

Indication

Rituxan® (rituximab) in combination with methotrexate is indicated for the treatment of adult patients with moderately to severely- active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.

Rituxan is not recommended for treatment of patients with severe active infections.

Important Safety Information

RITUXAN administration can result in serious, including fatal, adverse reactions. These include: infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML).

Warnings and Precautions

Rituxan administration can also result in additional serious, including fatal, adverse reactions including:

  • hepatitis B reactivation
  • other infections including bacterial, fungal, new or reactivated viral infections
  • cardiovascular events

Patients should be closely observed for signs of infection if biologic agents and /or DMARDs other than methotrexate are used concomitantly

Common adverse reactions include infusion reactions and infections

For additional safety information, please see the full prescribing information, including BOXED WARNINGS and Medication Guide.

Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN infusion.

Print Page
 

Infusion information

Rituxan has a familiar infusion setup that is similar to other IV infusions your staff administers

  • Rituxan is given in combination with methotrexate
  • Rituxan is administered as two 1000-mg IV infusions separated by 2 weeks
  • Glucocorticoids, administered as methylprednisolone 100 mg IV or its equivalent 30 minutes prior to each infusion, are recommended to reduce the incidence and severity of infusion reactions
  • The use of oral glucocorticoids provides no additional safety benefits
  • Premedication with acetaminophen and an antihistamine should be considered before each infusion of Rituxan
  • A Rituxan nurse can help train you and your staff prior to the first few Rituxan infusions
  • Infusion reactions may occur. In clinical trials, most were mild to moderate in severity and managed by slowing or stopping the infusion; less than 1% were serious

For full instructions on dosage and administration, please see the DOSAGE AND ADMINISTRATION section of the full prescribing information.